The Cooper Companies, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bearish -25

A Failed Auction and a 15% Drop: Is Cooper Companies (COO) a Value Trap or a Bargain?

Dividend Guidance lowered AI-generated analysis

πŸ“‰ Shares cratered ~15% to a 52-week low near $51 after the company abandoned its nine-month auction for CooperSurgical.

πŸ’° Management authorized a new $1 billion share repurchase program to signal conviction despite the failed sale.

πŸ‘οΈ Flat organic revenue growth at the core CooperVision contact lens business triggered the guidance cut.

πŸ“¦ The company initiated a reduction of U.S. channel inventory to establish a healthier foundation for fiscal 2027.

πŸ’΅ Record free cash flow of $273 million in Q3 expanded financial flexibility despite operational headwinds.

πŸ›οΈ Bank of America highlighted that the failed auction indicates buyers' unwillingness to meet management's valuation.

πŸ“Š Institutional interest increased slightly, with 52 hedge funds holding COO in Q2 2026 versus 49 in Q1.

βš–οΈ The stock trades at 18 times earnings, down roughly 40% from its high, raising questions about value trap status.

Bullish Signals
  • Management authorized a new $1 billion share repurchase program to signal conviction in the business.
  • Free cash flow for the third quarter hit a record $273 million, expanding financial flexibility.
  • Institutional interest showed a modest increase with 52 hedge funds holding COO in Q2 2026 compared to 49 in Q1.
Risk Factors
  • Shares dropped ~15% to a 52-week low near $51 following the abandonment of the CooperSurgical sale.
  • The company posted flat organic revenue growth at its core CooperVision contact lens business in Q3.
  • Management lowered its outlook due to simultaneous slowdowns in surgical assets and lens revenue.
  • Bank of America noted that the failed auction indicates buyers' unwillingness to meet management's valuation.
Full Analysis
The Cooper Companies (COO) shares dropped approximately 15% to a 52-week low near $51 following the abandonment of a strategic review for its CooperSurgical unit. Management ended the nine-month auction process in December 2025, citing that bids received did not reflect shareholder interests due to temporary headwinds like new competition and litigation expenses. Despite the failed sale, the board authorized a new $1 billion share repurchase program to signal confidence. The core issue remains performance at CooperVision, the company's primary contact lens business, which posted flat organic revenue growth in the third quarter. To normalize channel inventory ahead of fiscal 2027, the firm initiated a reduction in U.S. channel stock, contributing to a lowered outlook. However, free cash flow for the quarter hit a record $273 million, expanding financial flexibility despite the operational slowdown. Analyst sentiment is mixed regarding the valuation and future trajectory. Bank of America noted that the lack of a deal suggests buyers' unwillingness to meet management's valuation, leaving shareholders exposed to headwinds. Conversely, institutional interest showed a modest increase with 52 hedge funds holding the stock in Q2 2026 compared to 49 previously. The article concludes that if distributor destocking concludes smoothly and surgical pressures abate, the current low valuation supports accumulation.